Brief: AIM Immunotech Reports Additional Patient Data From Single-Center Named Patient Program Evaluating Ampligen
20/07/2022 14:28
July 20 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH REPORTS ADDITIONAL PATIENT DATA FROM
SINGLE-CENTER NAMED PATIENT PROGRAM EVALUATING AMPLIGEN AS
MAINTENANCE THERAPY FOR ADVANCED PANCREATIC CANCER INDICATING
ADDITIONAL PROGRESSION-FREE AND OVERALL SURVIVAL OVER PREVIOUSLY
PUBLISHED DATA
* AIM IMMUNOTECH - NEW PATIENT DATA PROVIDE FURTHER
VALIDATION FOR
ADVANCING DEVELOPMENT OF AMPLIGEN FOR TREATMENT OF LATE-STAGE
PANCREATIC CANCER
Source text for Eikon: ID:nGNXbFCM3Z
Further company coverage: AIM.A
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential